Development of a respirable, sustained release microcarrier for 5-fluorouracil I: In vitro assessment of liposomes, microspheres, and lipid coated nanoparticles

Journal of Pharmaceutical Sciences

Volumn 95, Issue 5, 2006, Pages 1114-1126

  Hitzman, Cory J ^a   Elmquist, William F ^a   Wattenberg, Lee W ^b   Wiedmann, Timothy S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

5 fluorouracil; Lipid coated nanoparticles; Liposomes; Lipospheres; Lung cancer; Microspheres; Sustained release

Indexed keywords

DRUG CARRIER; FLUOROURACIL; LIPID; LIPOSOME; MICROSPHERE; NANOPARTICLE; POLYGLACTIN; POLYLACTIDE; POLYMER;

ADJUVANT THERAPY; ARTICLE; DRUG DELIVERY SYSTEM; FILM; HYDRATION; IN VITRO STUDY; LIGHT SCATTERING; LUNG CANCER; MICRODIALYSIS; PARTICLE SIZE; SPRAY DRYING; SUSTAINED DRUG RELEASE;

EID: 33646564421     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20591     Document Type: Note

References (35)

1. American Cancer Society. 2003. Cancer facts and figures 2003. Atlanta, GA: American Cancer Society.
2. Fry WA, Phillips JL, Menck HR. 1999. The American College of Surgeons Commission on Cancer and the American Cancer Society ten-year survey of lung cancer treatment and survival in hospitals in the United States. Cancer 86:1867-1876.
3. Vaporcian AA, Nesbitt JC, Lee JS, Stevens CW, Komacki R, Roth JA. 2000. Cancer of the lung. In: Bast RC, Kufe DW, Pollock RE, Weischselbaum RR, Holland JF, Frei E, editors. Cancer medicine. Hamilton, Ontario: BC Decker, Inc., pp. 1227-1292.
4. Grem JL. 1990. Fluorinated pyrimidines. In: Chabner BA, Collins JM, editors. Cancer chemotherapy: Principles and practice. Philadelphia, PA: J.B. Lippincott Company, pp. 180-224.
5. Tanaka F, Fukuse T, Wada H, Fukushima M. 2000. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents. Curr Pharm Biotech 1:137-164.
6. Wattenberg LW, Wiedmann TS, Estensen RD. 2004. Chemoprevention of cancer of the upper respiratory tract of the syrian golden hamster by aerosol administration of difluoromethylornithine and 5-fluorouracil. Canc Res 64:2347-2349.
7. Raabe OG, Al-Bayati MA, Teague SV, Rasolt A. 1988. Regional deposition of inhaled monodispersed coarse and fine aerosol particles in small laboratory animals. Ann Occup Hyg 32:53-65.
8. Phalen RF, Cuddihy RG, Fisher GL, Moss OR, Schlesinger RB, Swift DL, Yeh HC. 1991. Main features of the proposed NCRP respiratory tract model. Rad Pro Dos 36:179-184.
9. Payne HR. 2001. Microemulsions, vesicles, and liposomes. In: Mollet H, Grubenmann A, editors. Formulation technology. New York, NY: John Wiley and Sons, pp. 112-122.
10. Taylor KMG, Farr SJ. 1993. Preparation of liposomes for pulmonary drug delivery. In: Gregoriadis G, editors. Liposome technology, 2nd Edn. Vol 1. Boca Raton, FL: CRC Press, pp. 177-195.
11. Ivey H, Roth S, Kattwinkel J. 1977. Nebulization of sonicated phospholipid for treatment of respiratory distress syndrome (RDS) of infancy. Ped Res 11:573-582.
12. McCullough HN, Juliano RL. 1979. Organ-selective action of an antitumor drug: Pharmacologic studies of liposome encapsulated cytosine arabinoside administered via the respiratory system of the rat. J Natl Canc Inst 63:727-735.
13. Juliano RL, McCullough HN. 1980. Controlled delivery of an antitumor drug: Localized action of liposome-encapsulated cytosine arabinoside administered via the respiratory tract. J Pharm Exp Ther 214:381-392.
14. Schreier H, Gonzalez-Rothi RJ, Stecenko AA. 1993. Pulmonary delivery of liposomes. J Cont Rel 24:209-223.
15. Tsapis N, Bennet D, Jackson B, Weitz DA, Edwards DA. 2002. Trojan particles: Large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci 99:12001-12005.
16. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R. 1997. Large porous particles for pulmonary drug delivery. Science 276:1868-1871.
17. O'Hara P, Hickey AJ. 2000. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Manufacture and characterization. Pharm Res 17:955-961.
18. Sharma R, Saxena D, Dwivedi AK, Misra A. 2001. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res 18:1405-1410.
19. Emerich DF, Snodgrass P, Lafreniere D, Dean RL, Salzberg H, Marsh J, Perdomo B, Arastu M, Winn SR, Bartus RT. 2002. Sustained release chemotherapeutic microspheres provide superior efficacy over systemic therapy and local bolus infusions. Pharm Res 19:1052-1060.
20. Domb AJ. 1993. Lipospheres for controlled delivery of substances, U.S. Patent 5,188,837, Feburary 23, 1993.
21. Cortesi R, Esposito E, Luca G, Nastruzzi C. 2002. Production of lipospheres as carriers for bioactive compounds. Biomaterials 23:2283-2294.
22. Pillai RS, Yeates DB, Miller IF, Hickey AJ. 1998. Controlled dissolution from wax-coated aerosol particles in canine lungs. J Appl Physiol 84:717-725.
23. Muhlen AZ, Schwarz C, Mehnert W. 1998. Solid lipid nanoparticles (SLN) for controlled drug delivery-Drug release and release mechanism. Eur J Pharm Biopharm 45:149-155.
24. Amselem S, Gabizon A, Barenholz Y. 1990. Optimization and upscaling of doxorubicin-containing liposomes for clinical use. J Pharm Sci 79:1045-1052.
25. Tatsumura T, Koyama S, Tsujimoto M, Kitagawa M, Kagamimori S. 1993. Further study of nebulization chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: Fundamental and clinical. Br J Cancer 68:1146-1149.
26. Khanna C, Anderson PM, Hasz DE, Katsanis E, Neville M, Klausner JS. 1997. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 79:1409-1421.
27. Khanna C, Hasz DE, Klausner JS, Anderson PM. 1996. Aerosol delivery of interleukin-2 liposomes is nontoxic and biologically effective: Canine studies. Clin Canc Res 2:721-734.
28. Hershey AE, Kurzman ID, Forrest LJ, Bohling CA, Stonerook M, Placke ME, Imondi AR, Vail DM. 1999. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: Proof of principle using dogs with spontaneously occurring tumors as a model. Clin Canc Res 5:2653-2659.
29. Hitzman CJ, Wiedmann TS, Dai H, Elmquist WF. 2005. Measurement of drug release from microcarriers by microdialysis. J Pharm Sci 94:1456-1466.
30. Ozer AY, Talsma H. 1989. Preparation and stability of liposomes containing 5-fluorouracil. Int J Pharm 55:185-191.
31. Fu YJ, Shyu SS, Su FH, Yu PC. 2002. Development of biodegradable co-poly(D,L-lactic/glycolic acid) Microspheres for the controlled release of 5-FU by the spray drying method. Coll Surf B: Biointerfaces 25:269-279.
32. Fu K, Pack DW, Klibanov AM, Langer R. 2000. Visual evidence of acidic environment within degrading poly(Lactic-co-Glycolic Acid) (PLGA) microspheres. Pharm Res 17:100-106.
33. Pitt CG. 1990. Poly-ε-caprolactone and its copolymers. In: Chasin M, Langer R, editors. Biodegradable polymers as drug delivery systems. New York: Marcel Dekker, pp. 71-120.
34. Nishida K, Ando Y, Yoshida H, Satake A. 1985. Interaction of 5-fluorouracil with sodium poly-α,L-Glutamate. Coll Poly Sci 263:682-685.
35. Hitzman CJ, Elmquist WF, Wiedmann TS. 2006. Development of a respirable, sustained release microcarrier for 5-fluorouracil II: In vitro and in vivo optimization of lipid coated nanoparticles. J Pharm Sci 95:1127-1143.